Intelligence · Clinical Development
Pipeline search results
Programs matching “eli lilly” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 169 pipeline programs matching "eli lilly" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
A Phase 1 Study on the effects of LY3410738 (...
Eli Lilly Co.
Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.
1 trial -
A Study of LY3200882 in Participants With Solid Tumors.
Eli Lilly Co.
Metastatic cancer, Solid Tumor
1 trial -
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly Co.
Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor
1 trial -
A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.
Eli Lilly Co.
Cancer
1 trial -
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Eli Lilly Co.
Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis
1 trial -
EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers
Eli Lilly Co.
Breast Cancer, Endometrial cancer
1 trial -
I3Y-MC-JPCE
Eli Lilly Co.
Lung Cancer or Breast Cancer
1 trial -
I3Y-MC-JPEI
Eli Lilly Co.
Prostatic Neoplasms
1 trial -
I8H-MC-BDDG
Eli Lilly Co.
Type 2 Diabetes Mellitus
1 trial -
Insulin Peglispro
Eli Lilly and Company
Healthy Volunteers
1 trial -
J1I-MC-GZQF
Eli Lilly Co.
Type 2 Diabetes Mellitus
1 trial -
J1I-MC-GZQG
Eli Lilly Co.
Diabetes Mellitus
1 trial -
J2S-MC-GZML
Eli Lilly Co.
Healthy, Hepatic Insufficiency
1 trial -
J3L-MC-EZEH
Eli Lilly Co.
Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment
1 trial -
J3R-MC-YDAH
Eli Lilly Co.
Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function
1 trial -
J4P-MC-IYAB
Eli Lilly Co.
Type 1 Diabetes Mellitus
1 trial -
J5J-OX-JZZA
Eli Lilly Co.
KRAS G12D-mutant solid tumors.
1 trial -
J5Q-OX-JRDA
Eli Lilly Co.
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.
1 trial -
J6B-MC-YKAA
Eli Lilly Co.
Healthy, Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2
1 trial -
J6I-MC-OWAA
Eli Lilly Co.
Sporadic Amyotrophic Lateral Sclerosis
1 trial -
JIO-MC-JZHD
Eli Lilly Co.
Neuroblastoma
1 trial -
LOXO-ENC-23001
Eli Lilly Co.
Advanced/metastatic solid tumor
1 trial -
LOXO-FRA-24001
Eli Lilly Co.
Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.
1 trial -
LOXO-IDH-20001
Eli Lilly Co.
Advanced Hematologic Malignancies
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.